Effects of Developmental Stage and Transitions on Drug Use Trajectories

项目描述：拟议研究的主要目标是调查发育阶段和过渡对药物使用轨迹的影响，并为成年初显期和成年早期设计预防方案，这是一个相对研究不足的人群。使用从大城市人口中收集的数据-代表性样本（N=1206，50%女性，40%中低收入，75%白色），该研究将进行二次数据分析，以了解药物使用风险的变化和预测四个不同发育时期这些变化的变量：青春期早期（P1：中学，或12-14岁），青春期后期（P2：高中，或15-18岁），成年初显期（P3：19-25岁）和成年期（P4：25岁以上），特别侧重于成年初显期过渡作为吸毒调节因素的影响。这项拟议的研究还将确定是否中介变量，特别是那些有针对性的干预计划，已被发现影响药物使用风险，通过青少年年有一个持续的中介关系，以药物使用在成年期，以及是否这些相同的变量与新兴的成年过渡。建议项目的目标是：1。探讨从青少年早期到成年的一系列发展阶段中物质使用的增长轨迹; 2.确定与不同发育时期物质使用增长轨迹相关的保护和风险因素; 3.研究年龄/阶段性转变、社会生活事件转变和环境生活事件转变对成年初显期物质使用行为的调节作用;探索性目标4。确定从青春期早期到成年初具有更显著药物使用风险轨迹的个体亚组。将使用最先进的以及新的探索性生长曲线建模变化来测试这些关系。这项研究预计将产生重要的方向，为那些通过药物使用风险变化确定的年轻人制定助推器和量身定制的预防计划。研究结果应推广到城市地区的年轻成年人。 公共卫生相关性：本项目的重点是增加我们对物质使用和风险轨迹与发展阶段和过渡的关系的理解，涵盖青春期早期到成年早期（从11岁到30岁）。这项研究将使用一个纵向随机预防试验数据集，收集了1987年至2005年期间的14波数据，以调查不同发育时期物质使用轨迹的关系，并确定与每个时期物质使用相关的关键因素。研究结果预计将告知有针对性的预防计划的发展，年轻的成年人，人口相对不足的预防，从而可能构成一个专门的健康差距组。

DESCRIPTION (provided by applicant): Effects of Developmental Stage and Transitions on Drug Use trajectories Project Description: The major goal of the proposed study is to investigate the effects of developmental stage and transitions on drug use trajectories, with implications for designing prevention programs for the emerging adulthood and early adulthood periods, a relatively understudied population for prevention. Using data collected on a large urban population-representative sample (N=1206, 50% female, 40% low-moderately low income, 75% white) from a longitudinal randomized substance use prevention trial, the study will conduct secondary data analyses to understand shifts in drug use risk and variables predictive of these shifts over four different developmental periods: early adolescence (P1: middle school, or age 12-14), late adolescence (P2: high school, or age 15-18), emerging adulthood (P3: age 19-25) and adulthood (P4: older than age 25), with a particular focus on the impact of emerging adulthood transitions as moderators of drug use. The proposed study will also determine whether mediating variables, especially those targeted by the intervention program, that have been previously found to affect drug use risk through the adolescent years have a sustained mediational relationship to drug use in adulthood, and whether these same variables are associated with emerging adulthood transitions. The aims of the proposed project are: 1. To examine the growth trajectories of substance use in a series of developmental periods from early adolescence to adulthood; 2. To identify protective and risk factors associated with the growth trajectories of substance use during different developmental periods; 3. To investigate moderation impacts of age/stage-based transition, social life event transition and environmental life event transition on substance use behavior during emerging adulthood; and an exploratory Aim 4. To identify subgroups of individuals with more salient drug use risk trajectories from early adolescence to emerging adulthood. State-of-the-art as well as new exploratory variations of growth curve modeling will be used to test these relationships. The study is expected to yield important directions for developing booster and tailored prevention programs for young adults who are identified by shifts in drug use risk. The findings should generalize to young adult populations from urban areas. PUBLIC HEALTH RELEVANCE: The present project focuses on increasing our understanding of the relationships of substance use and risk trajectories to developmental stages and transitions, over a life span covering early adolescence to early adulthood (from age 11 to 30). The proposed study will use a longitudinal randomized prevention trial data set with 14 waves of data collected between 1987 and 2005 to investigate the relationships of substance use trajectories in different developmental periods and identify critical factors associated with substance use at each period. Findings are expected to inform the development of targeted prevention programs for young adults, a population relatively understudied in prevention, and thus potentially constituting a specialized health disparities group.